招股书显示，博迈医疗专注于高性能血管介入医疗器械的研发、生产及全球销售，是全球行业内技术及 产品领先的复杂血管疾病介入治疗解决方案提供商，同时也是国产血管介入球囊导管领域产销量领先的 研发生产企业。 此次创业板IPO，博迈医疗拟募集资金17亿元，投向松山湖全球总部项目、湖南生产基地技改（一期） 项目、介入类医疗器械研发项目等5个项目。 北京商报讯（记者 丁宁）深交所官网显示，广东博迈医疗科技股份有限公司（以下简称"博迈医疗"） 创业板IPO进入已问询阶段。 ...

近日， 广东博迈医疗科技股份有限公司 （简称"博迈医疗"） 递交招股书，拟在深交所创业板上市。根据披露，公司计划募资 17 亿元 ，投向全球总部建设、生产基 地技改、介入类器械研发、营销网络建设及补充流动资金等多个方向。 结合其产品结构、财务表现与募资用途来看，博迈医疗正处在一个更为明确的阶段—— 从核心产品跑通，走向研发、制造与市场同步扩展的体系化发展期 。 # 以复杂血管介 入为 核心的产品 型公司 从业务边界来看，博迈医疗并非平台型医疗器械企业，而是一家定位清晰的 血管介入器械产品公司 。公司长期专注于高性能血管介入医疗器械的研发、生产与销 售，核心场景聚焦于复杂血管疾病的介入治疗。 招股书显示，博迈医疗的产品体系主要围绕介入导管与球囊展开，覆盖冠脉介入、外周介入、神经介入、血透通路等多个细分应用方向。其中， 血管介入球囊导管 是其长期投入、也是当前商业化基础最为稳固的产品类型。 这一定位决定了博迈医疗的发展路径：不是通过广泛铺设低壁垒产品线获取规模，而是围绕工程能力与制造工艺，在高一致性、高可靠性的介入耗材领域持续深 化。 早期阶段，公司以介入球囊导管等基础耗材切入临床市场，通过制造工艺、材料选择与一 ...

Group 1 - The establishment of the "China International Science and Technology Promotion Association Mother Fund Branch" aims to enhance the role of mother funds in China's capital market and promote the healthy development of the investment industry, particularly the mother fund sector [1][17][19] - The Fujian Provincial Specialized and New Mother Fund has a target scale of 2 billion RMB, focusing on innovative small and medium-sized enterprises and specialized "little giant" enterprises in key industries [2][4] - The fund provides positive incentives to sub-funds, allowing for a maximum profit-sharing of 50% of government contributions based on the development effectiveness of supported enterprises [2] Group 2 - The Hunan Jin Furong Industrial Guidance Fund focuses on investing in high-quality enterprises and key projects in the new materials industry to support the high-quality development of Hunan's new materials sector [4][6] - The Dongguan Science and Technology Innovation Continuation S Fund has completed an investment in Guangdong Boma Medical Technology Co., Ltd., marking its second project investment in its first year [6][7] - Boma Medical is recognized as a leading provider of complex vascular disease intervention solutions, with products covering over 100 countries [6][8] Group 3 - Shanghai Science and Technology Innovation Fund led a nearly 200 million RMB financing round for Weimei Technology, which focuses on AI solutions for clinical pain points [8][9] - The strategic cooperation agreement between China Guoxin and Hangzhou government aims to deepen cooperation in various fields, including fund investment and financial services [10][12] - Jiangsu Huanghai Jin控 Group has established a comprehensive strategic cooperation with Nanjing University of Information Science and Technology, focusing on climate science and marine technology innovation [13] Group 4 - China Resources Double Crane and Zhongshu Pharmaceutical signed a strategic cooperation agreement to enhance their partnership in the biopharmaceutical sector [14][15] - The collaboration aims to build a long-term stable strategic partnership and support the development of innovative pharmaceutical projects in Henan Province [15][16]